• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Rep . KLRB1 expression in nasopharyngeal mucosa as a prognostic biomarker in COVID-19 patients

tetano

Editor, Senior Moderator
Sci Rep


. 2025 Jan 24;15(1):3079.
doi: 10.1038/s41598-025-86846-7. KLRB1 expression in nasopharyngeal mucosa as a prognostic biomarker in COVID-19 patients

Marilina García-Aranda[SUP] 1 2 3 [/SUP], María Ángeles Onieva[SUP] 4 [/SUP], Desirée Martín-García[SUP] 5 6 7 [/SUP], Raúl Quirós[SUP] 8 [/SUP], Inmaculada López[SUP] 9 [/SUP], María Padilla-Ruiz[SUP] 5 7 [/SUP], Teresa Téllez[SUP] 5 6 [/SUP], Beatriz Martínez-Gálvez[SUP] 6 [/SUP], María Luisa Hortas[SUP] 10 [/SUP], Alberto García-Galindo[SUP] 11 12 [/SUP], José González-Gomariz[SUP] 11 12 [/SUP], Rubén Armañanzas[SUP] 11 12 [/SUP], Francisco Rivas-Ruiz[SUP] 5 7 [/SUP], Alfonso Serrano[SUP] 13 [/SUP], Isabel Barragán-Mallofret[SUP] #[/SUP][SUP] 14 15 [/SUP], Maximino Redondo[SUP] #[/SUP][SUP] 16 17 18 19 [/SUP]



Affiliations
Abstract

The resurgence of COVID-19 and the rise in severe outcomes emphasize the need for reliable prognostic markers to guide patient care and optimize ICU and hospital resources. This study investigates the potential of nasopharyngeal swabs to identify biomarkers that predict ICU admission or death in hospitalized COVID-19 patients. We analyzed nasopharyngeal exudates from 95 hospitalized patients in 2020 using high-plex RNA quantification on the NanoString[SUP]®[/SUP] nCounter platform. Comparative analysis identified four genes, with KLRB1 (Killer cell lectin like receptor B1) (Odds Ratio OR 0.5, 95% CI: 0.27-0.96), along with age (OR 3.3, 95% CI: 1.25-8.93) emerging as independent prognostic markers in multivariate analysis. These findings were validated using qRT-PCR in an independent cohort of 168 patients hospitalized in 2022. While univariate analysis identified a significant association between KLRB1 expression and vaccination status (p < 0.05), only low KLRB1 expression (OR 1.135, 95% CI: 1.0-1.280), and age (OR 1.033, 95% CI: 1.006-1.061) were confirmed as independent risk factors for ICU admission or death, regardless of other studied variables such as comorbidities, vaccination status, or smoking habits. Our findings suggest that KLRB1 expression could improve prognostic tools by identifying patients at higher risk upon admission. Incorporating KLRB1 into multiplex diagnostic kits alongside SARS-CoV-2 detection could streamline prognostic assessment, providing a more comprehensive and efficient approach to patient management.

Keywords: Biomarker; COVID-19; KLRB1; Nasopharyngeal mucosa; Prognosis.

 
Back
Top Bottom